Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Andrea Lopez-LopezCarmen M LabandeiraJose Luis Labandeira-GarciaAna MuñozPublished in: British journal of pharmacology (2020)
The present results suggest that ROCK is involved in the pathophysiology of LID and that ROCK inhibitors such as fasudil may be a novel target for preventing or treating LID. Furthermore, previous studies have revealed neuroprotective effects of ROCK inhibitors.